Gilead’s Lenacapavir, Takeda’s Maribavir Due For Oral Explanations At EMA
Executive Summary
The sponsors of four drugs were due or possibly due to appear before the European Medicines Agency to explain why their respective products merit EU-wide approval.
You may also be interested in...
AstraZeneca/Sanofi’s RSV Shot Among 13 Hopefuls Awaiting EU Verdict
Its crunch time for sponsors of more than a dozen products as the EMA meets to adopt opinions on several marketing authorization applications.
High-Stake Meetings With EMA In Store For Sponsors Of EU Filings
The sponsors of six drugs that are nearing the end of the regulatory review cycle in the EU could this week be asked to explain why the European Medicines Agency should recommend approving their products.
BioMarin’s Hemophilia Gene Therapy Among Nine Products On Track For EU-Wide Approval
Four orphan drugs and a new COVID-19 vaccine are among the latest products that the European Medicines Agency says should be approved.